4wdt - Revision history

OCA at 10:13, 14 December 2022

OCA — Wed, 14 Dec 2022 10:13:20 GMT

←Older revision		Revision as of 10:13, 14 December 2022
Line 3:		Line 3:
	<StructureSection load='4wdt' size='340' side='right'caption='[[4wdt]], [[Resolution\|resolution]] 1.50Å' scene=''>		<StructureSection load='4wdt' size='340' side='right'caption='[[4wdt]], [[Resolution\|resolution]] 1.50Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4wdt]] is a 1 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4WDT OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4WDT FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4wdt]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4WDT OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4WDT FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=WDT:2-NITRO-5-(PHENYLSULFONYL)PHENOL'>WDT</scene~~></td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=WDT:2-NITRO-5-(PHENYLSULFONYL)PHENOL'>WDT</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4wds\|4wds]], [[4wdu\|4wdu]], [[4wdv\|4wdv]], [[4wdw\|4wdw]], [[4wdx\|4wdx]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4wdt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wdt OCA], [https://pdbe.org/4wdt PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4wdt RCSB], [https://www.ebi.ac.uk/pdbsum/4wdt PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4wdt ProSAT]</span></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">AKR1C3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>~~	+
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Testosterone_17-beta-dehydrogenase_(NADP(+)) Testosterone 17-beta-dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.64 1.1.1.64] </span></td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4wdt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wdt OCA], [~~http~~://pdbe.org/4wdt PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4wdt RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4wdt PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4wdt ProSAT]</span></td></tr>	+
	</table>		</table>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/AK1C3_HUMAN AK1C3_HUMAN]] Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.	+	[https://www.uniprot.org/uniprot/AK1C3_HUMAN AK1C3_HUMAN] Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 28:		Line 25:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Amano, Y]]	+	[[Category: Amano Y]]
-	[[Category: Yamaguchi, T]]	+	[[Category: Yamaguchi T]]
-	~~[[Category: Aldo-keto reductase inhibitor]]~~	+
-	~~[[Category: Oxidoreductase-oxidoreductase inhibitor complex~~]]	+

OCA at 09:12, 23 May 2019

OCA — Thu, 23 May 2019 09:12:51 GMT

←Older revision		Revision as of 09:12, 23 May 2019
Line 1:		Line 1:

	==17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol==		==17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol==
-	<StructureSection load='4wdt' size='340' side='right' caption='[[4wdt]], [[Resolution\|resolution]] 1.50Å' scene=''>	+	<StructureSection load='4wdt' size='340' side='right'caption='[[4wdt]], [[Resolution\|resolution]] 1.50Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4wdt]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4WDT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4WDT FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4wdt]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4WDT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4WDT FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=WDT:2-NITRO-5-(PHENYLSULFONYL)PHENOL'>WDT</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=WDT:2-NITRO-5-(PHENYLSULFONYL)PHENOL'>WDT</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4wds\|4wds]], [[4wdu\|4wdu]], [[4wdv\|4wdv]], [[4wdw\|4wdw]], [[4wdx\|4wdx]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4wds\|4wds]], [[4wdu\|4wdu]], [[4wdv\|4wdv]], [[4wdw\|4wdw]], [[4wdx\|4wdx]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">AKR1C3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Testosterone_17-beta-dehydrogenase_(NADP(+)) Testosterone 17-beta-dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.64 1.1.1.64] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Testosterone_17-beta-dehydrogenase_(NADP(+)) Testosterone 17-beta-dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.64 1.1.1.64] </span></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wdt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wdt OCA], [http://pdbe.org/4wdt PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4wdt RCSB], [http://www.ebi.ac.uk/pdbsum/4wdt PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4wdt ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wdt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wdt OCA], [http://pdbe.org/4wdt PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4wdt RCSB], [http://www.ebi.ac.uk/pdbsum/4wdt PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4wdt ProSAT]</span></td></tr>
Line 27:		Line 28:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Amano, Y]]		[[Category: Amano, Y]]
	[[Category: Yamaguchi, T]]		[[Category: Yamaguchi, T]]
	[[Category: Aldo-keto reductase inhibitor]]		[[Category: Aldo-keto reductase inhibitor]]
		+	[[Category: Oxidoreductase-oxidoreductase inhibitor complex]]

OCA at 02:08, 11 March 2017

OCA — Sat, 11 Mar 2017 02:08:42 GMT

←Older revision		Revision as of 02:08, 11 March 2017
Line 1:		Line 1:
		+
	==17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol==		==17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol==
	<StructureSection load='4wdt' size='340' side='right' caption='[[4wdt]], [[Resolution\|resolution]] 1.50Å' scene=''>		<StructureSection load='4wdt' size='340' side='right' caption='[[4wdt]], [[Resolution\|resolution]] 1.50Å' scene=''>
Line 6:		Line 7:
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4wds\|4wds]], [[4wdu\|4wdu]], [[4wdv\|4wdv]], [[4wdw\|4wdw]], [[4wdx\|4wdx]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4wds\|4wds]], [[4wdu\|4wdu]], [[4wdv\|4wdv]], [[4wdw\|4wdw]], [[4wdx\|4wdx]]</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Testosterone_17-beta-dehydrogenase_(NADP(+)) Testosterone 17-beta-dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.64 1.1.1.64] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Testosterone_17-beta-dehydrogenase_(NADP(+)) Testosterone 17-beta-dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.64 1.1.1.64] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wdt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wdt OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4wdt RCSB], [http://www.ebi.ac.uk/pdbsum/4wdt PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wdt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wdt OCA], [http://pdbe.org/4wdt PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4wdt RCSB], [http://www.ebi.ac.uk/pdbsum/4wdt PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4wdt ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
Line 18:		Line 19:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4wdt" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==

OCA at 07:54, 10 June 2015

OCA — Wed, 10 Jun 2015 07:54:30 GMT

←Older revision		Revision as of 07:54, 10 June 2015
Line 10:		Line 10:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/AK1C3_HUMAN AK1C3_HUMAN]] Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.		[[http://www.uniprot.org/uniprot/AK1C3_HUMAN AK1C3_HUMAN]] Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Type 5 17beta-hydroxysteroid dehydrogenase (17beta-HSD5) is an aldo-keto reductase expressed in the human prostate which catalyzes the conversion of androstenedione to testosterone. Testosterone is converted to 5alpha-dihydrotestosterone, which is present at high concentrations in patients with castration-resistant prostate cancer (CRPC). Inhibition of 17beta-HSD5 is therefore considered to be a promising therapy for treating CRPC. In the present study, crystal structures of complexes of 17beta-HSD5 with structurally diverse inhibitors derived from high-throughput screening were determined. In the structures of the complexes, various functional groups, including amide, nitro, pyrazole and hydroxyl groups, form hydrogen bonds to the catalytic residues His117 and Tyr55. In addition, major conformational changes of 17beta-HSD5 were observed following the binding of the structurally diverse inhibitors. These results demonstrate interactions between 17beta-HSD5 and inhibitors at the atomic level and enable structure-based drug design for anti-CRPC therapy.
		+
		+	Structures of complexes of type 5 17beta-hydroxysteroid dehydrogenase with structurally diverse inhibitors: insights into the conformational changes upon inhibitor binding.,Amano Y, Yamaguchi T, Niimi T, Sakashita H Acta Crystallogr D Biol Crystallogr. 2015 Apr;71(Pt 4):918-27. doi:, 10.1107/S1399004715002175. Epub 2015 Mar 27. PMID:25849402<ref>PMID:25849402</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+
		+	==See Also==
		+	*[[Prostaglandin F synthase\|Prostaglandin F synthase]]
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>

OCA at 13:02, 15 April 2015

OCA — Wed, 15 Apr 2015 13:02:32 GMT

←Older revision		Revision as of 13:02, 15 April 2015
Line 1:		Line 1:
-	'''~~Unreleased structure~~'''	+	==17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol==
-		+	<StructureSection load='4wdt' size='340' side='right' caption='[[4wdt]], [[Resolution\|resolution]] 1.50Å' scene=''>
-	~~The entry~~ 4wdt is ~~ON HOLD until Paper Publication~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[4wdt]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4WDT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4WDT FirstGlance]. <br>
-	~~Authors~~: ~~Amano~~, Y., ~~Yamaguchi~~, T.	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=WDT:2-NITRO-5-(PHENYLSULFONYL)PHENOL'>WDT</scene></td></tr>
-		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4wds\|4wds]], [[4wdu\|4wdu]], [[4wdv\|4wdv]], [[4wdw\|4wdw]], [[4wdx\|4wdx]]</td></tr>
-	~~Description~~: ~~17beta~~-~~HSD5 in complex with 2~~-~~nitro~~-5-(~~phenylsulfonyl~~)~~phenol~~	+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Testosterone_17-beta-dehydrogenase_(NADP(+)) Testosterone 17-beta-dehydrogenase (NADP(+))], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.64 1.1.1.64] </span></td></tr>
-	[[~~Category~~: ~~Unreleased Structures~~]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wdt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wdt OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4wdt RCSB], [http://www.ebi.ac.uk/pdbsum/4wdt PDBsum]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/AK1C3_HUMAN AK1C3_HUMAN]] Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.
		+	__TOC__
		+	</StructureSection>
	[[Category: Amano, Y]]		[[Category: Amano, Y]]
	[[Category: Yamaguchi, T]]		[[Category: Yamaguchi, T]]
		+	[[Category: Aldo-keto reductase inhibitor]]

OCA at 19:22, 24 December 2014

OCA — Wed, 24 Dec 2014 19:22:26 GMT

←Older revision		Revision as of 19:22, 24 December 2014
Line 6:		Line 6:

	Description: 17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol		Description: 17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol
		+	[[Category: Unreleased Structures]]
		+	[[Category: Amano, Y]]
		+	[[Category: Yamaguchi, T]]

OCA at 06:53, 8 October 2014

OCA — Wed, 08 Oct 2014 06:53:01 GMT

←Older revision		Revision as of 06:53, 8 October 2014
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4wdt is ON HOLD	+	The entry 4wdt is ON HOLD until Paper Publication

	Authors: Amano, Y., Yamaguchi, T.		Authors: Amano, Y., Yamaguchi, T.

	Description: 17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol		Description: 17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol

OCA: Protected "4wdt" [edit=sysop:move=sysop]

OCA — Wed, 24 Sep 2014 09:10:36 GMT

Protected "4wdt" [edit=sysop:move=sysop]

←Older revision

Revision as of 09:10, 24 September 2014

OCA: New page: '''Unreleased structure''' The entry 4wdt is ON HOLD Authors: Amano, Y., Yamaguchi, T. Description: 17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol

OCA — Wed, 24 Sep 2014 09:10:34 GMT

New page: '''Unreleased structure''' The entry 4wdt is ON HOLD Authors: Amano, Y., Yamaguchi, T. Description: 17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol

New page

'''Unreleased structure'''

The entry 4wdt is ON HOLD

Authors: Amano, Y., Yamaguchi, T.

Description: 17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol